{"id":"placebo-vehicle","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo-vehicle serves as a negative control in clinical studies to establish baseline effects and distinguish true drug efficacy from placebo response. It contains the same inactive ingredients and delivery system as the active drug formulation but lacks the therapeutic agent itself. This allows researchers to measure the genuine pharmacological effect of the investigational drug.","oneSentence":"Placebo-vehicle is an inert control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:34.874Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03372811","phase":"PHASE2","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-IIb Trial)","status":"COMPLETED","sponsor":"Psoriasis Research Institute of Guangzhou","startDate":"2015-06-11","conditions":"Psoriasis Vulgaris, Topical Administration","enrollment":88},{"nctId":"NCT04520607","phase":"PHASE3","title":"A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee","status":"TERMINATED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2020-08-25","conditions":"Osteoarthritis, Knee","enrollment":276},{"nctId":"NCT07487363","phase":"PHASE1, PHASE2","title":"TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-05","conditions":"Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction","enrollment":80},{"nctId":"NCT05713877","phase":"PHASE2","title":"Melatonin for Treatment of Delirium in Critically Ill Adult Patients","status":"RECRUITING","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2023-02-01","conditions":"Delirium","enrollment":30},{"nctId":"NCT07482787","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa","status":"NOT_YET_RECRUITING","sponsor":"Paradigm Therapeutics","startDate":"2026-05-15","conditions":"Epidermolysis Bullosa (EB)","enrollment":80},{"nctId":"NCT07257029","phase":"PHASE2","title":"Topical Ketotifen 0.25% for Secondary Vestibulodynia","status":"RECRUITING","sponsor":"Center for Vulvovaginal Disorders","startDate":"2026-01-02","conditions":"Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia","enrollment":54},{"nctId":"NCT06789861","phase":"PHASE1","title":"A First in Human Study of TT5 in Single and Multiple Ascending Doses in Healthy Volunteers and Surgical Patients","status":"RECRUITING","sponsor":"Tafalgie Therapeutics","startDate":"2025-05-23","conditions":"Pain","enrollment":94},{"nctId":"NCT06146634","phase":"NA","title":"Washington State Driving Intervention Research Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2024-07-15","conditions":"Driving Behavior","enrollment":8000},{"nctId":"NCT07477782","phase":"PHASE2","title":"Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05","conditions":"Primary Sclerosing Cholangitis (PSC), Inflammatory Bowel Disease (IBD)","enrollment":72},{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT06568627","phase":"PHASE3","title":"A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)","status":"RECRUITING","sponsor":"MediWound Ltd","startDate":"2025-06-01","conditions":"Venous Leg Ulcer (VLU)","enrollment":216},{"nctId":"NCT07471178","phase":"PHASE4","title":"Mycological Efficacy and Safety of Ketoconazole 2% Shampoo With a Seven-Day Versus Three-Day Treatment Duration in Pityriasis Versicolor","status":"NOT_YET_RECRUITING","sponsor":"Fakultas Kedokteran Universitas Indonesia","startDate":"2026-02","conditions":"Pityriasis Versicolor","enrollment":76},{"nctId":"NCT00820820","phase":"NA","title":"IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-01-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT03104517","phase":"PHASE3","title":"Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cook MyoSite","startDate":"2019-04-23","conditions":"Stress Urinary Incontinence","enrollment":96},{"nctId":"NCT07469228","phase":"PHASE1","title":"A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-08-04","conditions":"Acne Vulgaris","enrollment":1043},{"nctId":"NCT05776277","phase":"PHASE3","title":"Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cook MyoSite","startDate":"2024-03-21","conditions":"Fecal Incontinence","enrollment":200},{"nctId":"NCT06542497","phase":"PHASE3","title":"Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-08-15","conditions":"Presbyopia","enrollment":569},{"nctId":"NCT03961347","phase":"PHASE2","title":"Lactobacillus Johnsonii Supplementation in Adults With T1D","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2020-02-01","conditions":"Type 1 Diabetes (T1D)","enrollment":46},{"nctId":"NCT05646719","phase":"PHASE3","title":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":333},{"nctId":"NCT06349759","phase":"PHASE3","title":"Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-04-01","conditions":"Mesopic Vision, Night Vision Loss","enrollment":200},{"nctId":"NCT06053138","phase":"NA","title":"Assessment of BHB Concentration Agreement Among Sampling Locations and the Impact of Ketosis on EPO, and More","status":"COMPLETED","sponsor":"Central Jutland Regional Hospital","startDate":"2023-08-24","conditions":"Ketosis","enrollment":16},{"nctId":"NCT07016750","phase":"PHASE3","title":"A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa","status":"RECRUITING","sponsor":"Krystal Biotech, Inc.","startDate":"2025-06-20","conditions":"Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa","enrollment":16},{"nctId":"NCT07384208","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5% in Patients With Acne Vulgaris (GEDACNE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"PPM Services S.A.","startDate":"2024-11-19","conditions":"Acne Vulgaris","enrollment":400},{"nctId":"NCT07384195","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Patients With Acne Vulgaris (GEDACNE-1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"PPM Services S.A.","startDate":"2024-11-19","conditions":"Acne Vulgaris","enrollment":400},{"nctId":"NCT06504160","phase":"PHASE1","title":"Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-10","conditions":"Atopic Dermatitis","enrollment":86},{"nctId":"NCT03961854","phase":"PHASE2","title":"Lactobacillus Johnsonii in Children and Adolescents With T1D","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-10-10","conditions":"Type 1 Diabetes (T1D)","enrollment":30},{"nctId":"NCT07447141","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2023-12-24","conditions":"Health, Health Adult Subjects","enrollment":44},{"nctId":"NCT07369869","phase":"NA","title":"Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress.","status":"NOT_YET_RECRUITING","sponsor":"Northumbria University","startDate":"2026-05","conditions":"Stress, Sleep, Cognition","enrollment":68},{"nctId":"NCT05171894","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT","status":"RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-09-21","conditions":"Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus","enrollment":84},{"nctId":"NCT07437586","phase":"PHASE2","title":"Topical GHK-Cu Gel for Acute Skin Wound Healing","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)","enrollment":60},{"nctId":"NCT07439419","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2024-08-18","conditions":"Healthy","enrollment":20},{"nctId":"NCT06286397","phase":"PHASE2","title":"Topical Anti-Androgens in Pilonidal Sinus Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-01-10","conditions":"Pilonidal Disease, Pilonidal Disease of Natal Cleft, Pilonidal Sinus","enrollment":75},{"nctId":"NCT07079969","phase":"PHASE2","title":"Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-04","conditions":"Knee Pain Chronic","enrollment":32},{"nctId":"NCT06999733","phase":"PHASE1, PHASE2","title":"A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis","status":"RECRUITING","sponsor":"Krystal Biotech, Inc.","startDate":"2025-07-07","conditions":"Neurotrophic Keratitis","enrollment":60},{"nctId":"NCT07430917","phase":"PHASE2","title":"Safety and Efficacy of J147 in Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Abrexa Pharmaceuticals, Inc.","startDate":"2026-03-20","conditions":"Acute Ischemic Stroke","enrollment":196},{"nctId":"NCT07431476","phase":"PHASE4","title":"Brimonidine 0.33% for Rosacea-Related Facial Erythema","status":"COMPLETED","sponsor":"Istanbul Training and Research Hospital","startDate":"2025-05-01","conditions":"Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic)","enrollment":45},{"nctId":"NCT07426120","phase":"PHASE3","title":"Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)","status":"RECRUITING","sponsor":"Psoriasis Research Institute of Guangzhou","startDate":"2026-02-01","conditions":"Psoriasis Vulgaris, Topical Administration, Phase III","enrollment":300},{"nctId":"NCT07281014","phase":"PHASE4","title":"Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-27","conditions":"Heart Failure","enrollment":20},{"nctId":"NCT07412587","phase":"NA","title":"Therapeutic Potential of Topical Latanoprost Acid in Hair Loss - Pilot, Proof-of-concept Study","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2015-07-08","conditions":"Androgenetic Alopecia (AGA), Telogen Effluvium, Female Pattern Hair Loss, Androgenic Alopecia","enrollment":29},{"nctId":"NCT05005845","phase":"PHASE2","title":"NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)","status":"COMPLETED","sponsor":"NFlection Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Cutaneous Neurofibroma, Neurofibromatosis 1","enrollment":199},{"nctId":"NCT06244316","phase":"PHASE2","title":"A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-01-22","conditions":"Dry Eye Disease","enrollment":317},{"nctId":"NCT07286487","phase":"NA","title":"Glycyrrhetinic Acid and Acute Irritant Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of Split, School of Medicine","startDate":"2026-03-01","conditions":"Irritant Contact Dermatitis","enrollment":30},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT03624062","phase":"PHASE1","title":"MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-08-31","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT03928184","phase":"PHASE3","title":"Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis","status":"COMPLETED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2019-05-17","conditions":"Knee Osteoarthritis","enrollment":501},{"nctId":"NCT03972592","phase":"PHASE2","title":"Topical Sirolimus in Cutaneous Lymphatic Malformations","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2019-06-05","conditions":"Vascular Malformations, Lymphatic Malformation","enrollment":55},{"nctId":"NCT06400459","phase":"PHASE1, PHASE2","title":"IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"IVIEW Therapeutics Inc.","startDate":"2024-06-25","conditions":"Dry Eye Disease","enrollment":150},{"nctId":"NCT02581085","phase":"PHASE2","title":"Tocotrienol Against the Progression of End Stage Liver Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chandan Sen","startDate":"2019-11-01","conditions":"End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease","enrollment":70},{"nctId":"NCT02633163","phase":"PHASE2","title":"Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2018-11-18","conditions":"Systemic Lupus Erythematosus","enrollment":81},{"nctId":"NCT07215767","phase":"PHASE3","title":"Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice","status":"RECRUITING","sponsor":"HALEON","startDate":"2025-09-16","conditions":"Dentin Hypersensitivity","enrollment":850},{"nctId":"NCT04385303","phase":"PHASE3","title":"Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)","status":"COMPLETED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2020-05-26","conditions":"Knee Osteoarthritis","enrollment":496},{"nctId":"NCT07160205","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)","status":"RECRUITING","sponsor":"Restem, LLC.","startDate":"2026-01-06","conditions":"Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS","enrollment":40},{"nctId":"NCT06594393","phase":"PHASE2","title":"A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study","status":"RECRUITING","sponsor":"Xinnate AB","startDate":"2026-01-30","conditions":"Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa","enrollment":32},{"nctId":"NCT05212246","phase":"PHASE3","title":"Basal Cell Carcinoma Chemoprevention Trial","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-05-01","conditions":"Basal Cell Carcinoma","enrollment":1630},{"nctId":"NCT07357870","phase":"PHASE1","title":"A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo","status":"RECRUITING","sponsor":"CAGE Bio Inc.","startDate":"2025-07-25","conditions":"Vitiligo","enrollment":36},{"nctId":"NCT05411367","phase":"PHASE3","title":"A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye","status":"COMPLETED","sponsor":"Seikagaku Corporation","startDate":"2022-07-28","conditions":"Dry Eye Disease","enrollment":232},{"nctId":"NCT07345390","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","startDate":"2026-01-10","conditions":"Acne Vulgaris","enrollment":180},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":"Nearsightedness, Near Sightedness, Near-sightedness","enrollment":852},{"nctId":"NCT03483246","phase":"PHASE3","title":"Impact of Fecal Microbiota Transplantation in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-17","conditions":"Ulcerative Colitis","enrollment":150},{"nctId":"NCT03573401","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biofrontera Inc.","startDate":"2018-09-25","conditions":"Superficial Basal Cell Carcinoma","enrollment":187},{"nctId":"NCT05066997","phase":"PHASE2, PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2021-10-19","conditions":"Diabetic Macular Edema","enrollment":552},{"nctId":"NCT06172257","phase":"PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2024-03-15","conditions":"Diabetic Macular Edema","enrollment":401},{"nctId":"NCT03727022","phase":"PHASE2","title":"Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis","status":"COMPLETED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2018-11-28","conditions":"Knee Osteoarthritis","enrollment":101},{"nctId":"NCT05361733","phase":"PHASE1","title":"A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.","status":"NOT_YET_RECRUITING","sponsor":"Xfibra, Inc.","startDate":"2026-01-15","conditions":"Focus of the Study: Safety of XFB19","enrollment":40},{"nctId":"NCT07005180","phase":"PHASE2","title":"Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Hillhurst Biopharmaceuticals, Inc.","startDate":"2026-02-28","conditions":"Parkinson Disease","enrollment":36},{"nctId":"NCT06400511","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment","status":"TERMINATED","sponsor":"Famy Life Sciences, a Viatris Company","startDate":"2024-04-22","conditions":"Blepharitis","enrollment":477},{"nctId":"NCT07319117","phase":"NA","title":"Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure.","status":"RECRUITING","sponsor":"Leeds Beckett University","startDate":"2025-12-15","conditions":"Cognitive Assessment, Working Memory, Executive Function (Cognition)","enrollment":40},{"nctId":"NCT05514340","phase":"PHASE2","title":"Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy","status":"RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2023-09-06","conditions":"Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia, Neonatal Encephalopathy","enrollment":40},{"nctId":"NCT05691244","phase":"PHASE3","title":"Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke","status":"RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2025-07-24","conditions":"Acute Ischemic Stroke, Cerebral Stroke","enrollment":514},{"nctId":"NCT05251181","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent","status":"NOT_YET_RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2026-02","conditions":"Hypovolemic Shock","enrollment":430},{"nctId":"NCT07287033","phase":"PHASE1","title":"Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy","status":"RECRUITING","sponsor":"Mabylon AG","startDate":"2025-12-06","conditions":"Peanut Allergies","enrollment":48},{"nctId":"NCT06899230","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007","status":"ACTIVE_NOT_RECRUITING","sponsor":"iQure Australia Pty Ltd","startDate":"2025-04-08","conditions":"Drug Resistant Epilepsy, Focal Seizure","enrollment":72},{"nctId":"NCT07301515","phase":"NA","title":"Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin","status":"COMPLETED","sponsor":"Klira Skin","startDate":"2025-03-01","conditions":"Photoaging, Photodamage, Mitochondrial Damage","enrollment":52},{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT06832618","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-17","conditions":"Atopic Dermatitis","enrollment":240},{"nctId":"NCT06742957","phase":"PHASE3","title":"Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2024-12-17","conditions":"Plaque Type Psorisis","enrollment":560},{"nctId":"NCT07280299","phase":"PHASE2","title":"Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Gain Therapeutics, Inc.","startDate":"2026-05-30","conditions":"Parkinson Disease","enrollment":111},{"nctId":"NCT03140254","phase":"PHASE2","title":"Evaluating Safety and Effectiveness of Octenidine Dihydrochloride","status":"COMPLETED","sponsor":"C. R. Bard","startDate":"2016-09","conditions":"Preoperative Skin Preparation","enrollment":145},{"nctId":"NCT06393452","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA","status":"COMPLETED","sponsor":"Pelage Pharmaceuticals, Inc.","startDate":"2024-06-05","conditions":"Androgenetic Alopecia","enrollment":78},{"nctId":"NCT02724566","phase":"PHASE1","title":"Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2016-05","conditions":"Diabetes","enrollment":9},{"nctId":"NCT03608033","phase":"PHASE3","title":"Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy","status":"TERMINATED","sponsor":"Omeros Corporation","startDate":"2018-04-05","conditions":"IgA Nephropathy","enrollment":360},{"nctId":"NCT07219771","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients","status":"RECRUITING","sponsor":"Doron Therapeutics Inc.","startDate":"2025-10-14","conditions":"Knee Osteoarthritis","enrollment":260},{"nctId":"NCT07244887","phase":"PHASE4","title":"Randomized, Triple-Blind, Placebo-Controlled Trial of Topical Dapsone Gel in Patients With Acne Vulgaris","status":"ENROLLING_BY_INVITATION","sponsor":"Oya Helin Dundar","startDate":"2025-06-17","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT05190770","phase":"PHASE2","title":"A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-15","conditions":"Breast Cancer, Breast Cancer Stage, Breast Cancer Stage I","enrollment":18},{"nctId":"NCT06845839","phase":"PHASE1","title":"Study to Evaluate CAY001 in Healthy Volunteers","status":"RECRUITING","sponsor":"Cayuga Biotech, Inc.","startDate":"2025-12-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT07259538","phase":"PHASE1","title":"A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray","status":"RECRUITING","sponsor":"VivaVision Biotech, Inc","startDate":"2025-11-06","conditions":"Chronic Rhinosinusitis (CRS)","enrollment":60},{"nctId":"NCT07245017","phase":"EARLY_PHASE1","title":"JN002 for the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-11-24","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT07254663","phase":"","title":"GEL & MEDication Dysphagia","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2025-09-15","conditions":"Neurological Diseases or Conditions, Healthy Participants","enrollment":500},{"nctId":"NCT04735393","phase":"PHASE3","title":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-01-26","conditions":"Dry Eye Disease","enrollment":757},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT07220408","phase":"PHASE2","title":"Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2025-10-23","conditions":"Allergic Conjunctivitis","enrollment":60},{"nctId":"NCT03332238","phase":"PHASE2","title":"Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-01","conditions":"Rotator Cuff Tear, Muscle Atrophy, Tendon Tear","enrollment":56},{"nctId":"NCT07203274","phase":"NA","title":"The Role of Janus Kinase (JAK) and Voltage-gated Sodium Channels (Nav) on Pain and Itch","status":"NOT_YET_RECRUITING","sponsor":"Aalborg University","startDate":"2025-12-01","conditions":"Itchiness","enrollment":30},{"nctId":"NCT05618782","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Levicept","startDate":"2022-10-19","conditions":"Pain, Osteo Arthritis Knee, Knee Osteoarthritis","enrollment":518},{"nctId":"NCT06744569","phase":"PHASE1","title":"A Phase I Clinical Trial to Evaluate CU-10101 Unguent","status":"ENROLLING_BY_INVITATION","sponsor":"Cutia Therapeutics（Wuxi）Co.,Ltd","startDate":"2024-09-12","conditions":"Atopic Dermatitis","enrollment":64},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT02059759","phase":"PHASE2","title":"Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2015-09","conditions":"Amyotrophic Lateral Sclerosis","enrollment":36},{"nctId":"NCT05802173","phase":"PHASE2","title":"Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Technoderma Medicines Inc.","startDate":"2023-03-06","conditions":"Alopecia, Androgenetic","enrollment":71},{"nctId":"NCT05330078","phase":"EARLY_PHASE1","title":"Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2022-03-11","conditions":"Keloid","enrollment":10},{"nctId":"NCT05142267","phase":"NA","title":"Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-03-02","conditions":"Opioid Use Disorder, Back Pain, Stress","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":249,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo-vehicle","genericName":"Placebo-vehicle","companyName":"Aarhus University Hospital","companyId":"aarhus-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}